PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy. - Liu, M. C.; Pitcher, B. N.; Mardis, E. R.; Davies, S. R.; Snider, J. E.; Vickery, T.; Reed, J. P.; DeSchryver, K.; Singh, B.; Friedman, P. N.; Gradishar, W. J.; Perez, E. A.; et al. (Cancer Research, 2012)